547 related articles for article (PubMed ID: 9042164)
21. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
22. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
Hagel C; Krog B; Laas R; Stavrou DK
J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
[TBL] [Abstract][Full Text] [Related]
23. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
Kamiya M; Nakazato Y
Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
[TBL] [Abstract][Full Text] [Related]
24. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
25. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas.
Kirla RM; Haapasalo HK; Kalimo H; Salminen EK
Cancer; 2003 Feb; 97(3):644-8. PubMed ID: 12548606
[TBL] [Abstract][Full Text] [Related]
26. Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations--a study of 32 cases.
Avninder S; Sharma MC; Deb P; Mehta VS; Karak AK; Mahapatra AK; Sarkar C
J Neurooncol; 2006 Jun; 78(2):123-7. PubMed ID: 16614946
[TBL] [Abstract][Full Text] [Related]
27. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
28. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
29. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas.
Angileri FF; Aguennouz M; Conti A; La Torre D; Cardali S; Crupi R; Tomasello C; Germanò A; Vita G; Tomasello F
Cancer; 2008 May; 112(10):2258-66. PubMed ID: 18327814
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis of pediatric astrocytic tumors.
Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies.
Torp SH
Clin Neuropathol; 2002; 21(6):252-7. PubMed ID: 12489673
[TBL] [Abstract][Full Text] [Related]
32. p53 and PTEN gene mutations in gemistocytic astrocytomas.
Watanabe K; Peraud A; Gratas C; Wakai S; Kleihues P; Ohgaki H
Acta Neuropathol; 1998 Jun; 95(6):559-64. PubMed ID: 9650746
[TBL] [Abstract][Full Text] [Related]
33. [Fraction of gemistocytic astrocytes and immunoexpression of p53 protein in astrocytomas grade II and III (WHO)].
Martins DC; Stávale JN; Malheiros SM; Santiago LH; Roman LC; Aguiar KC
Arq Neuropsiquiatr; 2001 Dec; 59(4):926-31. PubMed ID: 11733839
[TBL] [Abstract][Full Text] [Related]
34. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
[TBL] [Abstract][Full Text] [Related]
35. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.
Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H
Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587
[TBL] [Abstract][Full Text] [Related]
36. Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
Malhan P; Husain N; Bhalla S; Gupta RK; Husain M
Indian J Pathol Microbiol; 2010; 53(1):20-3. PubMed ID: 20090216
[TBL] [Abstract][Full Text] [Related]
37. Gemistocytes in astrocytomas: are they a significant prognostic factor?
Martins DC; Malheiros SM; Santiago LH; Stávale JN
J Neurooncol; 2006 Oct; 80(1):49-55. PubMed ID: 16645716
[TBL] [Abstract][Full Text] [Related]
38. Expression of the p53 protein in a spectrum of astrocytic tumours.
Ellison DW; Gatter KC; Steart PV; Lane DP; Weller RO
J Pathol; 1992 Dec; 168(4):383-6. PubMed ID: 1336544
[TBL] [Abstract][Full Text] [Related]
39. Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas.
Ohta T; Kim YH; Oh JE; Satomi K; Nonoguchi N; Keyvani K; Pierscianek D; Sure U; Mittelbronn M; Paulus W; Vital A; Yokoo H; McDonald K; Kleihues P; Nazaret N; Barbet F; Lachuer J; Ohgaki H
J Neuropathol Exp Neurol; 2014 Oct; 73(10):908-15. PubMed ID: 25192052
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas.
Kordek R; Biernat W; Debiec-Rychter M; Alwasiak J; Liberski PP
Pathol Res Pract; 1996 Mar; 192(3):205-9. PubMed ID: 8739466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
